Error loading player: No playable sources found
4390
FDA Town Hall
Date
May 20, 2024
SOCIETY: AGA The AGA-FDA Town Hall provides health care professionals, clinical trial investigators, and other interested stakeholders an opportunity to hear directly from FDA representatives about the agency's thinking behind recent approvals, safety signals, guidance documents, and boxed warnings for GI drugs. This session was jointly developed by AGA and representatives of the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research.
Moderators
Middleburg Consultants
University of Tennessee Health Science Center
Related Products
AGA Drivers and Triggers of Visceral Pain in Intestinal Inflammation
Visceral pain is a leading cause of disability worldwide, affecting 20% of the population. Increased sensitivity to normal innocuous stimuli in the intestine is a hallmark of many organic and functional gastrointestinal disorders…
Donald O. Castell, MD, Lecture: GERD Diagnosis from Lyon to Chicago to Padova: Do All Roads Eventually Lead to Rome?
The diagnosis of GERD is being updated using the Lyon Consensus 2.0 (updated in 2023), which takes into account a modern diagnosis of GERD, symptoms of GERD, optimal testing as well as metrics and thresholds used to diagnose conclusive GERD…
Tadataka “Tachi†Yamada, MD, Lecture: Food as Medicine: How to Utilize Diet and Enhance Nutrition to Improve Outcomes in Foregut Diseases
LIVE STREAM SESSION This session will review evidence-based dietary approaches to management of patients with common foregut diseases including gastroesophageal reflux disease, eosinophilic esophagitis, and motility disorders of the esophagus and stomach…
Irritable Bowel Syndrome in Inflammatory Bowel Disease: Boundaries Along a Continuum
SOCIETY: AGA IBS-like symptoms in patients with IBD are common, yet presenting a diagnostic and clinical challenge for patients and their providers…
